|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA and EMA (2016)) |
IUPAC Name ![]() |
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
9925 | venetoclax |
Synonyms ![]() |
ABT-199 | GDC-0199 | Venclexta® | Venclyxto® |
Comments |
Venetoclax is a BH3 mimetic that selectively targets Bcl-2 [4], utilised for its pro-apoptotic activity. It is noteworthy that venetoclax is the first approved medicine designed to induce a natural process that helps cells self-destruct. The IUPAC name provided by PubChem matches 'Example 5' claimed in patent US8580794 [1]. |
Database Links ![]() |
|
CAS Registry No. | 1257044-40-8 |
ChEMBL Ligand | CHEMBL3137309 |
GtoPdb PubChem SID | 252166530 |
PubChem CID | 49846579 |
Search Google for chemical match using the InChIKey | LQBVNQSMGBZMKD-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | LQBVNQSMGBZMKD |
Search PubMed clinical trials | venetoclax |
Search PubMed titles | venetoclax |
Search PubMed titles/abstracts | venetoclax |
Search UniChem for chemical match using the InChIKey | LQBVNQSMGBZMKD-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | LQBVNQSMGBZMKD |